Drug class
Endoglycosidase; Programmed Death Receptor-1 Blocking Antibody; Glycoside Hydrolases
Mechanism of action
Programmed Death Receptor-1-directed Antibody Interactions [MoA]
General use cases
- Mesothelioma, Malignant
- Biliary Tract Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
